N-乙基他达拉非 | 1609405-34-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: N-乙基他达拉非
• 中文别名: N-乙基他达那非
• 英文名称: N-Ethyl tadalafil
• 英文别名: (2R,8R)-2-(1,3-benzodioxol-5-yl)-6-ethyl-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione
• CAS: 1609405-34-6
• 化学式: C₂₃H₂₁N₃O₄
• 分子量: 403.4
• InChiKey: QGNIMKVVHAXCSK-VGOFRKELSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  30
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES
  申请人：FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA

  公开号：US20160002246A1

  公开（公告）日：2016-01-07

  It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B 1 is a radical selected from the group consisting of formula (A″), formula (B″), formula (C″), and formula (D″):

  它涉及到一些具有多环结构和羟胺酸基团的化合物，其中多环结构包括至少三个环系统，其中一个环系统是由2至4个环组成的多环环系统；至少一个环是芳香环；结构中包含至少3个氮原子和1个氧原子。它还涉及到它们的制备过程，以及包含它们的制药组合物，以及它们在医学上的应用，特别是在治疗和/或预防伴随认知缺陷或损伤或神经退行性疾病的神经系统疾病中。其中B1是从公式（A''）、公式（B''）、公式（C''）和公式（D''）组成的基团。
• NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT
  申请人：FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA

  公开号：US20170217973A1

  公开（公告）日：2017-08-03

  Novel compounds for use in cognition improvement It relates to certain compounds having a polycyclic structure and a —(C═O)NR a R b moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neared-generative diseases.
• US9573956B2
  申请人：——

  公开号：US9573956B2

  公开（公告）日：2017-02-21
• US9969744B2
  申请人：——

  公开号：US9969744B2

  公开（公告）日：2018-05-15